Clinical prognostic factors and survival outcome of chronic myelomonocytic leukemia: reviewing 3,686 patients

We read with interest the paper of Subari et al1 in which they evaluated the difference of survival outcome between therapy-related chronic myelomonocytic leukemia (CMML) and De Novo CMML. They revealed that therapy-related CMML patients had poorer survival than De Novo CMML (median OS; 11 vs. 20 months, p=0.02).

Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Mohamed Abd El-Fattah Tags: Letter to the Editor Source Type: research